«In this study, we showed that cancer stem cells co-opt
a RNA editing system to clone themselves.
Not exact matches
Researchers are currently working to improve the components of the CRISPR
system — its gene - cutting enzyme and the
RNA that guides the enzyme to the right gene — to increase the efficiency of
editing.
This cell's gene -
editing system targets
RNA, revealing the molecule's distribution in the cytoplasm.
The gene -
editing success appears to be largely due to one procedural change: The researchers introduced the
editing system — the enzyme Cas9 and a guide
RNA sequence that helps the
editing machinery find its target — at the same time they injected the mutation - laden sperm into a healthy egg in the lab.
Researchers have previously harnessed this
system to create gene -
editing complexes composed of a DNA - cutting enzyme called Cas9 and a short
RNA that guides the enzyme to a specific area of the genome, directing Cas9 where to make its cut.
The company aims to use CRISPR gene -
editing to craft
RNA therapeutics that can be delivered into the central nervous
system — clearly a daunting task for most drug makers.
«But this new paper provides much more information and raises interesting ideas — instead of just using regular old genome evolution,
RNA editing might have been a way to produce molecular diversity, particularly in their nervous
systems.
Our study reveals a family of endonucleases that use dual -
RNAs for site - specific DNA cleavage and highlights the potential to exploit the
system for
RNA - programmable genome
editing.
This means that it could conceivably form part of an
editing system to tag
RNA so that its movement in the cell can be tracked.
For
editing the genome, this
system makes use of 3 components, a guide
RNA (gRNA) of about 125 nt that specifies the target, the Cas9 endonuclease that creates the DNA double - strand break (DSB) at the target site, and a donor oligonucleotide or plasmid as the repair material if needed (for knock in models).
Dubbed «REPAIR» this
system also focuses on base
editing but this time is targeted at
RNA.
Using the technology, Pal's lab has made many seminal contributions, including evidence for the existence of the nuclear - encoded plastid transcription
system and identification of key elements involved in promoter recognition, translational initiation, and
RNA editing site specificity.
The STS - PCRseq method pioneered by Stephane Bentolila provides a global method to analyze
RNA editing in plant mitochondrial and chloroplast transcripts, and can be adapted for use in any biological
system in order to sequence a selected subset of transcripts.
The UK patents relate to the CRISPR - Cas9 gene
editing systems involving single - guide
RNA in both non-cellular and cellular settings (UK Patent No. 2518764) and chimeric CRISPR - Cas9
systems in which the Cas9 protein is modified to provide alternative DNA - modulating activities (UK Patent No. 2537000).
Engineered CRISPR
systems for gene
editing now contain two main components, a single guide
RNA or sgRNA and Cas - 9 nuclease.
The Broad Institute and MIT scientists who first harnessed CRISPR for mammalian genome
editing have engineered a new molecular
system for efficiently
editing RNA in human cells.
With her recent groundbreaking findings in the field of
RNA - mediated regulation based on the CRISPR - Cas9
system, E. Charpentier has laid the foundation for the development of a novel, highly versatile and specific genome
editing technology that is revolutionizing life sciences research and could open up whole new opportunities in biomedical gene therapies.
The recent development of the CRISPR / Cas9
system for genome
editing enables the construction of
RNA - guided gene drives that may be capable of spreading nearly any alteration that can be made with Cas9.
New «REPAIR»
system edits RNA, rather than DNA; has potential to treat diseases without permanently affecting the genome
CRISPR - Cas9, a
system used to
edit DNA sequences, can be used on
RNA in living cells.
Published in Science, an exciting paper describes a new CRISPR - based gene
editing system that targets
RNA, the molecule responsible for translating DNA into protein, instead of DNA.
Cas9 is the endonuclease enzyme part of CRISPR / Cas9
system that cuts the DNA, while
RNA is the CRISPR guide, directing the enzyme to specific sites in the genome so that precise genome
edits are possible.
(LA JOLLA, CA)-- August 4, 2016 — Researchers from the J. Craig Venter Institute (JCVI) and Synthetic Genomics, Inc. (SGI) have published research describing a method for engineering Mycoplasma mycoides 16S ribosomal
RNA (rRNA) using a one - step process that combines CRISPR / Cas9 gene
editing system with yeast recombination machinery.